breast-cancer

Why mutation-targeted breast cancer drugs often disappoint—and what the next wave gets right.

Applying Christensen's disruptive innovation framework to breast cancer therapy: mutation-anchored agents underperform due to resistance escape routes, while broadly acting host-driven therapies (ADCs, immunotherapy, cell/gene therapies) succeed by acting through harder-to-escape mechanisms across…

Dan Manning

Dan Manning

— 1 min read
Share
Why mutation-targeted breast cancer drugs often disappoint—and what the next wave gets right.

Why mutation-targeted breast cancer drugs often disappoint—and what the next wave gets right.

Applying Christensen's disruptive innovation framework to breast cancer therapy: mutation-anchored agents underperform due to resistance escape routes, while broadly acting host-driven therapies (ADCs, immunotherapy, cell/gene therapies) succeed by acting through harder-to-escape mechanisms across patient subgroups.

Key Findings

  • Mutation-anchored therapies often underperform due to resistance
  • ADCs, immunotherapy, and cell/gene therapies show scalable durable impact
  • Subtype-agnostic modalities serve wider populations
  • Disruptive innovation framework illuminates oncology development dynamics

Implications

Future breakthroughs more likely from broad-acting platforms. Supports prioritizing ADCs and immunotherapy in development pipelines.

Caveats

Perspective piece; not a clinical study; abstract-only. Some mutation-targeted agents have been highly successful.

Source: Med — 2026-04-10

Read more